ECM
ALDX icon

Element Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Element Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,431
Closed -$123K – 813
2018
Q1 		$123K Buy
+16,431
New +$125K ﹤0.01% 764

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Element Capital Management's ALDX Position: Q2 2018 in Review

Element Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2018, closing a stake of 16,431 shares — an estimated $123K sold.

Element Capital Management first reported a position in ALDX in Q1 2018 and held it in 1 quarter. The position peaked at $123K in Q1 2018. 66 funds tracked by Wall St. Rank hold ALDX as of Q2 2018.

  • Element Capital Management reported no remaining Aldeyra Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 16,431 Aldeyra Therapeutics shares in Q2 2018, an estimated $123K.
  • Element Capital Management first reported a position in Aldeyra Therapeutics in Q1 2018 and held it in 1 quarter.
  • Element Capital Management's Aldeyra Therapeutics position peaked at $123K in Q1 2018.
  • 66 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.